Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents

Next Previous
Trial Profile

Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary) ; Aspirin
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms SMART-CHOICE

Most Recent Events

  • 20 Nov 2023 Results of Sex-Based Outcomes of treatment , After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention, published in the Journal of Korean Medical Science
  • 26 Jun 2023 Results of post hoc analysis (n = 1,840 of the hypertension cohort) assessing effect of P2y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with Hypertension presented at the 32nd European meeting on hypertension and cardiovascular protection
  • 19 Sep 2022 Results of post hoc analysis assessing effect of P2Y12 inhibitor monotherapy vs prolonged DAPT among patients with hypertension undergoing PCI presented at the Transcatheter Cardiovascular Therapeutics 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top